Latest Safety Reporting News

Orora says strong Cans growth is no longer enough to offset weaker Saverglass earnings, with Group EBIT expected to decline in FY27. The company is targeting more than €30 million in Glass EBIT improvement by FY30 after a €449.7 million non-cash impairment.

Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.

Mineral Resources Limited (ASX: MIN) closed FY26 exceeding volume and cost guidance across iron ore, lithium, and mining services, while bolstering liquidity and reducing net debt. Strategic investments at Mt Marion and Bald Hill signal ongoing growth.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

DGR Global Limited’s Q3 2025 report reveals ongoing project development, strategic equity holdings, and complex legal proceedings shaping its resource company creation model.

Sandfire Resources delivered a standout FY25 with a 12% rise in copper equivalent production and a 46% jump in underlying EBITDA, while slashing net debt by 69%. The company sets a confident FY26 outlook with modest production growth and continued capital discipline.

Fortescue Metals Group reported record iron ore shipments for the nine months to March 2025, alongside strategic acquisitions and progress in green energy projects.